Aldosterone and progression of renal disease
- 1 January 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Nephrology and Hypertension
- Vol. 17 (1), 44-50
- https://doi.org/10.1097/mnh.0b013e3282f29028
Abstract
The aim of this review is to look at the role of aldosterone in the progression of chronic kidney disease. The reduction of blood pressure and proteinuria in patients suffering from chronic kidney disease decreases the rate of disease progression. Suppression of angiotensin formation by angiotensin converting enzyme inhibitors and blockade of the angiotensin II receptor by angiotensin II type 1 antagonists are powerful therapeutic strategies that effectively lower blood pressure and slow the progression of renal disease. These therapies, however, provide only imperfect protection, since they cannot always prevent endstage renal failure. Aldosterone plays a significant role in the pathogenesis of arterial hypertension and renal disease. Angiotensin converting enzyme inhibitors and angiotensin II type 1 antagonists are incomplete in suppressing aldosterone production and 'aldosterone breakthrough' can be observed under continued treatment. Aldosterone blockade reduces blood pressure in virtually all patients with hypertension. In proteinuric patients, the addition of an aldosterone antagonist to an angiotensin converting enzyme inhibitor or to angiotensin II type 1 antagonists reduces proteinuria. The use of aldosterone antagonists in addition to either angiotensin converting enzyme inhibitors or angiotensin II type 1 antagonists in proteinuric patients reduces proteinuria, which may translate into preservation of the glomerular filtration rate in the longer term. Therefore, blockade of the aldosterone pathway may prove to be a beneficial therapy for chronic kidney disease.Keywords
This publication has 25 references indexed in Scilit:
- Aldosterone antagonists: Silver bullet or just sodium excretion and potassium retention?Kidney International, 2007
- Aldosterone Antagonism in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2006
- Use of Aldosterone Antagonists in Resistant HypertensionProgress in Cardiovascular Diseases, 2006
- Double-Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist Spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor BlockerClinical Journal of the American Society of Nephrology, 2006
- Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With HypertensionHypertension, 2005
- Aldosterone blockade in cardiovascular diseaseHeart, 2004
- Nongenomic Vascular Action of Aldosterone in the Glomerular MicrocirculationJournal of the American Society of Nephrology, 2003
- Spironolactone in Addition to ACE Inhibition to Reduce Proteinuria in Patients with Chronic Renal DiseaseNew England Journal of Medicine, 2001
- Role of aldosterone in the remnant kidney model in the rat.JCI Insight, 1996
- Clinical characteristics of primary aldosteronism from an analysis of 145 casesThe American Journal of Surgery, 1964